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Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart 
failure with reduced ejection fraction and leads to improved quality of life, reductions in heart 
failure hospitalization rates and reduces all-cause mortality. Nevertheless, up to two-thirds of 
eligible patients are not referred for CRT. Furthermore, post implantation follow-up is often 
fragmented and suboptimal, hampering the potential maximal treatment effect. This joint 
position statement from three ESC Associations, HFA, EHRA and EACVI focuses on 
optimized implementation of CRT. We offer theoretical and practical strategies to achieve 
more comprehensive CRT referral and post-procedural care by focusing on four actionable 
domains; (I) overcoming CRT under-utilization, (II) better understanding of pre-implant 
characteristics, (III) abandoning the term „non-response‟ and replacing this by the concept of 
disease modification, and (IV) implementing a dedicated post-implant CRT care pathway.  
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Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart 
failure  with reduced ejection fraction (HFrEF) resulting in improved quality of life, beneficial 
reverse remodeling and reductions in heart failure hospitalization rates and all-cause 
mortality.(1-7) Despite its well established clinical benefits and cost effectiveness, it remains 
a widely underutilized treatment option; recent Europe data suggest only 1 in 3 eligible 
patients actually receives a CRT device.(8) In contrast, the topic of „non-response‟ to CRT 
(“failure to improve”) has received disproportionally large research attention, with rates of 
non-response reported in 30% of implanted patients.(9) A binary definition of „response‟ 
classified by arbitrary magnitudes of improvements in a variety of variables of questionable 
clinical significance underestimates the true benefits of CRT reported in the randomized 
clinical trials. This is in contrast with the message from all randomized controlled CRT trials 
in HFrEF patients with a QRS > 130 msec, which consistently show a spectrum of 
stabilization or improvement of disease progression to even recovery of the disease.(10, 11) 
Moreover, in addition to this „failure to refer‟, optimization of both the device and the care of 
the patient following implant is hampered by a lack of integration of cardiological and non-
specialist care, leading to suboptimal and variable post-implant management.(12, 13) As a 
result, many heart failure patients are not exposed to the full potential benefit of CRT. This 
position paper aims to improve the implementation of CRT and follow-up of patients with 
CRT, by addressing the following topics; (i) underutilization of CRT, (ii) redefining response 
as disease modification of heart failure, (iii) better understanding of pre-implant patient 














B. Action plan for referral and optimization of CRT related care 
1. Action I:  overcome the underutilization of CRT 
 
Eligibility vs actual implantation 
Observational data indicate that 35 to 40% of patients with HFrEF have a prolonged QRS 
width (classically defined as QRS>120 ms) and 20-30% of HFrEF patients have LBBB.(14, 
15) Since a considerable proportion of HFrEF patients do not tolerate or improve after other 
heart failure therapies have been introduced, ultimately 5-10% of all heart failure patients 
remain eligible for CRT. As such, estimates using eligibility criteria as stated in professional 
practice guidelines (QRS>130 ms) suggest that up to 400 patients per million inhabitants of 
European countries might be candidates for CRT implantation annually.(16, 17) Between 
2005 and 2013, European and US guideline indications have expanded to also include patients 
with less severe symptoms (NYHA class II), and in 2016 the guidelines tightened the 
proportion of patients eligible to CRT by prolonging the QRS duration and altering the 
morphology criteria.(18) Data from the EHRA White Book indicate that within the European 
Union between 2010 and 2013 the average implantation rate varied between 106-123 per 
million inhabitants,(8) and more recent data from device registries reported a rate of 56 CRT-
P and 119 CRT-D implants per million inhabitants in 2018 in Europe, with a slight increase of 
mainly CRT-P over recent years (Figure 1). Although significant geographical differences are 
clearly present, these data suggest that up to two thirds of those eligible for CRT on current 
guidelines are not implanted. Registry data provide some insights into factors associated with 
the non-referral of CRT, indicating that older age (>75 years), lack of CRT implant centers, 
shorter duration of heart failure, absence of a heart failure nurse and non-cardiology follow-up 
are factors that are independently associated with non-delivery of CRT.(19) One key issue is 
that many patients with heart failure including those eligible for CRT are managed in primary 
or non-specialist care where there is possibly less familiarity with the indications and benefits 










of CRT.(17) This lack of awareness is also illustrated in the recent Euro CRT survey II, which 
highlighted that most of those implanted had been identified within the cardiology 
department. Only a minority had been referred from other departments, including primary 
care.(20) Moreover, despite the well-established benefit of CRT in women, CRT remains 
underused in female patients. This gender gap has remained unchanged in Europe over the 
past 10 years with female CRT patients representing only 27% and 24% of all implants in the 
ESC CRT Survey I and II, respectively.  
 
Guidelines vs registries 
Professional practice guidelines have formulated recommendations for CRT in HFrEF 
patients based upon morbidity and mortality reductions.(12, 21-24) Guidelines offer a strong 
level of recommendation for patients in sinus rhythm, a wide QRS-duration or LBBB. Data 
from the EuroCRT Survey II indicates that 67% of implanted patients had a class I indication, 
with 26% having a class IIa indication, 5% a class IIb indication and 2% a class III indication. 
It would appear that while CRT is globally underused, in clinical practice CRT is frequently 
offered to patients in whom the level of evidence is either less robust than a class I indication 
or non-existent.(25)  
 
Health economic considerations 
Implantable devices such as CRT are often approached with scrutiny by health care regulating 
agencies and payers, due to their significant up-front cost and the fact that they are implanted 
in a patient population (if left untreated) with a relatively limited life expectancy. The cost of 
any intervention needs to balance the willingness to pay, which is typically reflected in the 
incremental cost-effectiveness ratio (ICER). This is expressed as the amount of money which 
has to be spent to gain a quality adjusted life-year. A Markov-model with Monte-Carlo 
simulation from the CARE-HF and COMPANION trials indicates an ICER of €7,538 for 










CRT-P and €18,017 for CRT-D, which is below the generally accepted thresholds for cost-
effectiveness (€30,000-40,000 or gross domestic product (GDP) per capita) in high income 
countries.(26) In the REVERSE trial focusing on NYHA-class II patients, CRT was linked to 
0.94 life years or 0.80 QALYs at an additional cost of €11 455, yielding an incremental cost-
effectiveness ratio of €14.278 per quality-adjusted life year (QALY) gained.(27) Despite the 
additional upfront cost of a CRT-D device in comparison to a CRT-P device, it is still within 
the accepted cost-effectiveness boundaries for the USA and Europe.(27, 28) Data from the 
EHRA-white book indicate lower utilization of CRT in European countries with a lower GDP 
per capita,(8) suggesting that supportive guidelines aiding appropriate selection between 
CRT-P versus CRT-D in lower GDP-countries might help to increase CRT implant rates in 
these areas. 
 
Strategies to overcome the underutilization of CRT 
Since one of the barriers to implantation is referral, improved strategies to identify potential 
eligible CRT candidates by cardiologists and non-cardiologists are urgently needed.(20) 
Importantly, electrocardiogram surveillance in heart failure patients is warranted as 
abnormalities (which often change over time) not only provide information on etiology, but 
they also help to identify appropriate therapy. Furthermore, thorough and repeated education 
within primary and secondary care (including cardiologists less familiar with devices) about 
CRT, and openly addressing deeply-rooted myths that contribute to non-referral may improve 
CRT-implementation. (see table 1). Finally, deeper engagement with patient associations or 
support groups could improve the dissemination of information about therapeutic options. 
Screening through automated alerts in electronic health records based on information from 
QRS duration, LV function and heart failure status might trigger more actionable referrals. 
Given the expansion of electronic health records, screening for patients eligible for 










optimisation of heart failure therapy including CRT might be effective as it has been for other 
treatments for heart failure.(18, 29)  
 
2. Action II: replace “response to CRT” by “disease modification by CRT”  
Due to the upfront cost, life-long presence of the device, and potential device and procedure 
related complications, decisions for device based interventions are often delayed until all 
other non-device based therapies have „failed‟.(30) This situation is exacerbated by the unique 
and widespread concept of „non-response‟ where, based upon arbitrary cut-offs of remodeling 
(most often LV-end systolic volume reduction of > 15%) or symptomatic „improvement‟, it 
has been suggested that one-in-three patients do not „respond‟ to CRT. As a result of these 
factors, CRT  has been approached with an unprecedented scrutiny despite its firmly 
established benefits on morbidity and mortality in patients with heart failure and a wide QRS 
(>130ms).(31, 32) This situation is especially worrisome since no consensus exists on how or 
when to measure response to CRT and what magnitude of change constitutes response.(33) 
Adding to the confusion is a long list of potential „predictors of response‟ of which many are 
based upon results of observational studies, which, due to a lack of control data, cannot 
conclusively determine the relation between the predictor and the clinical outcome benefit 
(risk reduction) from CRT.  
 
Response parameters, agreement and timing  
Numerous variables including functional, event-based, imaging or composite outcomes have 
been used to describe response to CRT.(12) The importance of certain metrics might also 
differ according to the stakeholders, such as patients, their carers, doctors, payers or industry. 
The placebo effect of an implant on functional outcomes is also often underestimated as noted 
after implantation during the run-in phase before LV only pacing was switched on in the 










GREATER-EARTH study.(34) Moreover, the agreement between outcomes is remarkably 
poor. It is well recognized that resting LV function is poorly related to exercise capacity or 
symptoms (35), so it is not surprising that LV reverse remodeling poorly relates to the degree 
of functional improvement in many studies.(36-38) Indeed, the size and shape of the ventricle 
is irrelevant for patients complaining of exercise intolerance. Yet, LV reverse remodeling 
remains a commonly used endpoint, largely based upon the close relationship between 
changes in LV structure and outcomes.(39) However, these data have been over interpreted to 
imply that patients without significant LV reverse remodeling (e.g. LV end systolic volume 
reduction > 15%), derive no benefit from CRT whereas up to 30% of patients lacking 
remodeling benefits will experience an improvement in symptoms. Importantly, even patients 
who fail to demonstrate reverse remodeling and require a heart failure admission, still derive 
hemodynamic benefit from their device, as they often deteriorate when biventricular pacing is 
temporarily stopped. (40) Finally, the REVERSE trial showed a continuous reduction of both 
LV systolic and diastolic volumes for at least up to 2 years after CRT, which questions the 
appropriateness of any point-in-time assessment of therapy efficacy.(41) 
 
Baseline variables suggested to predict outcome following CRT  
In addition to the difficulty of timing, magnitude, congruity and outcome in assessing 
„response‟, there is a plethora of pre-implantation features that are associated with certain 
response parameters and often wrongly drive decisions on implantation. Commonly quoted 
features predicting less LV reverse remodeling in observational studies include male sex, 
ischemic etiology, high LV volumes, low glomerular filtration rate, and absence of 
mechanical dyssynchrony.(42-46) In contrast, post-hoc analyses of the major CRT-trials 
powered for mortality and morbidity (CARE-HF, RAFT, COMPANION and MADIT-CRT) 
revealed no heterogeneity between these aforementioned baseline characteristics and benefits 










on mortality or heart failure admission. Therefore, these subgroups gain similar relative risk 
reduction with CRT despite lesser degrees of LV reverse remodeling, and should not be used 
to deselect patients from receiving CRT.(3, 4, 6, 47). More importantly, these patients often 
have a high risk for heart failure admission and mortality (baseline event rate) and might 
actually therefore have a higher absolute risk reduction after CRT. None of the studies have 
shown an adverse effect of CRT in patients with a QRS-width above 130msec, especially in 
the LBBB population.(48, 49). Finally, in the recent ADVANCE-CRT registry, patients 
labeled as responders, were less likely to have their therapy optimized following CRT-
implant,(13) suggesting that there are risks from suboptimal care delivery if someone is 
actually labeled a responder. 
 
Removing the term ‘response’ 
Apart from rare isolated situations, heart failure is incurable. CRT is therefore not a curative 
therapy but rather should be seen as a treatment to ameliorate the contribution of 
electromechanical dyssynchrony to the heart failure syndrome in the hope that this will 
ultimately reduce heart failure related morbidity and mortality. A slowing of a progressive 
disease is a positive outcome (see Figure 2). Despite frequently quoted parallels between heart 
failure and cancer, the important concepts of “remission” and „non-progression‟ seem not to 
have permeated to cardiology. Therefore, this position statement calls to stop the current 
binary approach of CRT response, but rather we suggest that CRT should be classified as a 
treatment for „disease modification‟. One step towards such an approach is the Packer 
hierarchical scoring system which takes into account (lack of) mortality, (lack of) hospital 
admission for heart failure and stable functional status (without additional diuretic therapy), 
where lack of deterioration and therefore „stability‟ is seen as a positive outcome (see 
supplemental figure).(50) Furthermore, it needs to be underscored that if CRT is being 










implanted in HFrEF patients with a QRS-width above 130 msec (especially in the presence of 
LBBB), there is no proven patient population that experiences a negative response to 
CRT.(10)  
 
3. Action III: Better clinical interpretation of pre-implant characteristics 
 
Patient selection 
European and American guidelines give a class I recommendation for CRT in symptomatic 
HFrEF patients in sinus rhythm with wide QRS (supplemental table 1).(23, 24, 51) The 
EchoCRT and RethinQ trials showed that the benefit of CRT does not extend to patients with 
a narrow QRS, even in the presence of some echocardiographic characteristics indicative of 
LV mechanical dyssynchrony.(48, 52) The 2016 HFA-guidelines reflect these data and do not 
recommend CRT in patients with a narrow QRS, defined as QRS < 130msec (Class of 
recommendation III, level of evidence A).(48, 49) The observation that QRS duration is 
dependent on body/heart size has resulted in ongoing research to determine if QRS duration 
should be individualized.(53-55) 
Guidelines recommend the presence of LV ejection fraction (LVEF) below 35%, as 
this was a major inclusion criterion in most CRT trials. (23, 24, 51) However, there is reason 
to believe that CRT may be effective in the higher range of reduced LVEF from both the 
MADIT CRT and REVERSE trial.(56) For example, a core lab assessment of baseline LVEF 
from the MADIT-CRT trial indicated that 38% of patients actually had a LVEF above the 
entry-criteria cut-off, with LVEFs up to 45%.(57) These patients had similar benefit in terms 
of death and heart failure hospitalization, and might also have a greater degree of reverse 
remodeling. This, together with the standard error of the measurement of LVEF by 
echocardiography, should be taken into account when determining eligibility based upon 
LVEF.  










It is well acknowledged that visible pre-implant mechanical dyssynchrony (apical 
rocking, septal flash) is associated with an acute hemodynamic improvement following CRT. 
(58, 59) However, using mechanical dyssynchrony for the selection of CRT does not select 
patients more likely to gain benefit.(48, 49, 60) As such, the absence of pre-implant 
mechanical dyssynchrony should not defer the implantation of a CRT device in patients with 
a guideline indication. Other imaging techniques or echocardiographic parameters have not 
been used to guide treatment in the randomized controlled trials, and should therefore not be 
used for the de-selection of patients otherwise eligible. That is not to say however, that pre-
implant imaging is not required. For instance, pre-implant magnetic resonance imaging is 
useful in the assessment of the risk for sudden cardiac death (e.g; mid-wall fibrosis), and 
might therefore be helpful in determining the choice between CRT-P vs. CRT-D.(61, 62) 
Additionally, echocardiography remains an indispensable tool to detect disease progression 
following CRT, and the mechanism(s) related to ongoing disease following implant, which 
might be amenable for auxiliary therapies (e.g. residual functional mitral regurgitation 
amendable for mitral edge-to- edge repair).(63, 64)  
Guidelines state a IIa indication for CRT in patients with atrial fibrillation (AF), 
despite the fact that only 262 patients with AF were randomized in the original CRT-trials, 
which indicates that there is virtually no randomized trial data on CRT in AF patients.  The 
RAFT trial randomized patients to an ICD vs CRT-D stratified by the presence of permanent 
AF. In the AF patients, there was only a trend towards fewer heart failure hospitalization in 
CRT treated patients, and the primary outcome of death or heart failure hospitalization 
between those assigned to ICD vs CRT-D was similar.(65) Despite this limited trial evidence, 
up to 26% of patients enrolled into the Euro CRT Survey II had AF.(20) Furthermore 
guidelines state that a pre-requisite for CRT to work in AF is a strategy to ensure  bi-
ventricular capture is in place.(23, 24, 51) Observational data indicate that AF with rapid 










conduction is the leading reason for loss of biventricular pacing.(66, 67) Furthermore, 
observational studies relate a low percentage of biventricular to poor outcome. Although this 
is often interpreted that a strategy that ensures 100% of biventricular pacing results in better 
prognosis, it needs to pointed out that the phenotype of patients that suffer from low 
percentages of biventricular pacing might be sicker. This could partially explain the observed 
relation between biventricular pacing percentages and outcome. Indeed to data, no 
randomized trial study has proven that a higher number of biventricular pacing is better than a 
lower percentage of biventricular pacing. 
 Device based features have been designed to attain higher percentages of bi-
ventricular pacing through fusion pacing (RV sense will result in LV pacing), but should not 
be an alternative to optimal medical therapy, PVI or AV-junction ablation to ensure effective 
CRT in AF. Gasparini demonstrated in a small prospective study that CRT patients in 
permanent AF, only had improvement in LV function and functional capacity if AV-junction 
ablation was performed.(68) Furthermore, AV-junctional ablation has been associated with a 
reduced incidence of inappropriate ICD interventions.(69) The use of AV-junctional ablation 
in clinical practice is variable, but should be considered if pharmacologic therapies fail to 
result in adequate percentage (target of >90-95%) of biventricular pacing. The current 
position paper recognizes the scarce data of CRT in AF. Nevertheless, despite the lack of 
large randomized clinical trials, guidelines as well as this position statement still recommend 
the use of CRT in permanent AF patients with similar indications as for patients in sinus 
rhythm, provided that AVJ ablation (or PVI if indicated) is added in those with incomplete 
(<90-95%) biventricular pacing. (67, 70, 71). In addition, other causes for incomplete 
biventricular pacing such as premature ventricular beats might need to be treated as well. 
RAFT-PermAF (NCT01994252), which investigates whether CRT reduces heart size in CRT 
patients with permanent AF is currently ongoing.  










Next to selected patients in sinus rhythm and AF, guidelines recommend CRT in 
HFrEF patients with a classic pacing indication who are expected to receive a high burden of 
RV-pacing (IA-recommendation) or patients with a classic pacemaker or ICD who develop 
heart failure (IIa-recommendation for upgrade). (23, 24, 51)  In the Euro CRT II Survey, 23% 
of the entire CRT-population were upgrades.(20) ACC/AHA/HRS guidelines underscore that 
a high burden (eg >40%) of RV-pacing is a prerequisite for benefit of an upgrade. Few data 
are available from clinical trials. CRT was superior to conventional right ventricular pacing in 
patients in sinus rhythm with atrioventricular block and LV systolic dysfunction in the 
BLOCK-HF trial.(72) Additionally, reduced clinical manifestations of heart failure were 
noted with CRT pacing compared to RV pacing in heart failure patients with symptomatic 
permanent AF who underwent AV-junction ablation in the APAF trial.(73) Given the 
incremental risk of device upgrade or risk of pacemaker dependency after AV-junction 
ablation, the benefits and risks should be assessed individually given the rather low level of 
evidence. The ongoing BUDAPEST-CRT trial (NCT02270840) will determine the effects of 
upgrade from an ICD to a CRT-D in symptomatic HFrEF patients with RV-pacing 
(>20%).(74)  
 
Guideline directed medical therapy 
The evidence for CRT lies with HFrEF patients with residual symptoms and a persistently 
reduced LVEF despite optimal background treatment with neurohormonal blockers. However, 
only a minority of patients implanted with CRT are on maximal guideline recommended 
doses of ACE-I/ARB (30%) and beta-blockers (20%) before CRT.(75) Although this might be 
the result of inertia in care, patients might not be able to tolerate higher doses due bradycardia 
and hypotension. While patients with HFrEF and narrow QRS often exhibit significant 
reverse remodeling to medical therapy, patients with HFrEF and LBBB seem to reverse 










remodel less following initiation of neurohormonal blockers.(76) For example, in one study, 
patients with LBBB experienced an improvement in LVEF of 2% whereas those with a 
narrow QRS had an increase of 8% after 6 months of medical therapy which might be the 
result of differential expression of contractile genes in those with electromechanical 
dyssynchrony.(76, 77) Therefore, this position statement from HFA, EHRA and EACVI 
encourages clinicians not to postpone CRT implant too long, particularly in patients with 
LBBB and a QRS duration >150ms. 
 
Role of comorbidities  
Comorbidities are frequent in heart failure and affect the delivery and effect of heart failure 
therapy, functional status, and clinical outcomes.(78-81) Due to this competing risk patients 
with comorbidities derive less benefit from an ICD (see next section). However, an elegant 
analysis from the MADIT-CRT trial demonstrated that this was not the case for CRT, where 
the relative reduction in morbidity and mortality was consistent.(82) Hence, patients with 
comorbidities should not be denied CRT, although appropriate assessment of potential benefit 
of the combination of CRT with ICD therapy is particularly important in this population.(83)  
Certain comorbidities are of particular interest in CRT candidates as they might 
influence the success of the implantation procedure, choice between CRT-P vs. CRT-D, 
symptomatic improvement, and reverse remodeling response after implant.(12) Although a 
history of valve replacement might make LV lead placement more challenging, it is not 
associated with less benefit from CRT.(84, 85) Furthermore, while renal disease was an 
exclusion criteria in the major CRT trials and early observational data suggested less reverse 
remodeling in patients with chronic kidney disease stage IV and V,(1, 3-6, 47) more recent 
data indicate that patients with chronic kidney disease derive similar mortality benefit from  
lesser reverse remodeling.(31, 45) Iron deficiency which is common in CRT recipients 










(around 55%) might be associated with less functional improvement and less reverse 
remodeling following CRT,(86) possibly due to the role of iron as an essential co-factor for 
protein synthesis and normal cell functioning.(87)  
In conclusion, CRT selection and optimization must occur in the context of other heart 
failure interventions and other comorbidities. With a growing heart failure treatment 
armamentarium, this is becoming increasingly challenging for the cardiologist, highlighting 
the need for early referral to a heart failure management team. (18, 29) 
 
CRT-P vs CRT-D: individualizing choice 
In order to derive maximal benefit from a ICD, patients need to have a high risk of dying from 
sudden cardiac death (SCD) mediated by ventricular arrhythmias, and a low risk of dying 
from other causes (non-SCD-mediated death).(88-90) This balance should be taken into 
account prior to device implantation (figure 3). For example, large areas of scar and an 
ischemic etiology of heart failure or a high burden of non-sustained ventricular 
tachyarrhythmias  (NsVT) on Holter monitoring are associated with a higher risk of SCD.(61, 
91-95) Monitored SCD in patients with a CRT-P device is often pre-dated by an increasing 
burden of NsVTs, suggesting a role for remote monitoring to detect patients‟ who might 
benefit from upgrade to a CRT-D.(96). On the other hand, women have a lower risk of 
SCD,(97) and data from the DANISH trial illustrate that a strategy for routine primary 
prevention ICD for patients with a non-ischemic etiology does not improve overall long-term 
survival.(98) This is in line with other studies indicating that the risk for SCD is intrinsically 
lower in patients with a non-ischemic etiology of heart failure.(99)  Notably, there was an 
age-by-therapy interaction in DANISH suggesting that younger patients (possibly those 
younger than 70 years) have a greater chance of benefiting from ICD implantation than older 
patients probably because of lower competing risk from co-morbidities and the higher 










duration of exposure to the risk of SCD, which is reflected in the lower rate of SCD and all-
cause mortality.(100-102) Finally, accurate estimation of the risk of life-threatening 
ventricular tachyarrhythmias by risk calculators in patients with underlying genetic mutations 
(i.e. LMNA mutations) helps to select candidates for ICD implantation.(103)  CRT-D comes 
at higher cost and carries the risk of inappropriate therapy (104) and all post-hoc analyses 
including a Bayesian network analysis suggest equivalence between the two approaches but 
the randomized controlled trials also point at a favorable effect of CRT alone on the risk of 
sudden death. For example, the CARE-HF and REVERSE-trial indicate that 
resynchronization therapy, and its potential to increase beta-blocking agents, diminishes 
VT/VF, especially in patients with  extensive LV reverse remodeling,(105) possibly due to 
diminished electrical dispersion, early after depolarization and other cellular substrates for 
VT/VF.(106-108) Therefore, although factors associated with greater reverse remodeling 
following CRT, such as LBBB-morphology, long QRS-duration, female sex and non-
ischemic etiology should not be used to select candidates for CRT, they could be considered 
in the decision to offer CRT-P over CRT-D.(Figure 3). Advanced cardiac imaging 
technologies including assessment of conduction channels by cardiac resonance imaging and 
possibly radiomics may further help in individualizing risk of VT/VF in the future. Additional 
clinical factors favoring the use of CRT-P could include advanced age , more severe 
symptoms (NYHA class III/IV), and life-shortening co-morbidity (e.g. severe lung disease or 
Stage IV chronic kidney disease). Nevertheless, the difficult and currently unanswered 
paradox remains that whilst CRT reduces the need for ICD, it improves survival and reduces 
the rate of death due to HF, thereby exposing patients to an increased duration of life in which 
SCD can occur.  
As such, individualized decision making based on patient characteristics, 
national/local resources, and patient preference for either CRT-P or CRT-D remains important 










given the lack of head-to-head trials. Supportive guidelines aiding appropriate selection 
between CRT-P versus CRT-D in countries with lower GDP might help to increase CRT 
implant rates in these areas. The Re-evaluation of Optimal Re-synchronisation Therapy in 
Patients With Chronic Heart Failure (RESET-CRT, NCT03494933) trial will further provide 
information regarding this topic. 
 
5. Action IV: organize a dedicated post-implant optimized CRT care pathway 
Follow-up of CRT patients is often divided over several cardiology subspecialties and large 
differences exist between hospitals and healthcare systems.(109) Although a comprehensive 
post-CRT implant follow-up program has not been tested in randomized controlled trials, 
there are several easily-modifiable factors applicable directly following implant, before 
discharge, at early and longer follow-up that could improve short and longer-term outcomes 
following implantation (Figure 4 and Table 2).(110, 111). Furthermore, although such a 
comprehensive dedicated CRT follow-up program is endorsed by several cardiac societies 
(EHRA, Heart Rhythm Society, Heart Failure Society of America, American Society of 
Echocardiography, American Heart Association, EACVI and HFA), and results in 
improvement of workflow of a typical multi-morbid complex patient population, an ongoing 
barrier is the need for focused training of medical and allied health care professionals in the 
holistic care of patients with heart failure and device-based interventions.(112) Such training 
has been endorsed by the European HFA and forms part of the certification by the 
EHRA.(113, 114) Interestingly, just as referral for CRT is inadequate, referral for further 
interventions in patients who already have CRT is also inadequate, underscoring the 
importance of broad knowledge of the CRT-team/CRT-expert. For example, it has been 
shown that the need for heart transplantation and LV assist device was grossly underestimated 










among patients followed in CRT/ICD clinics.(18, 29) The remainder of this section discusses 
major topics in the optimization of care following CRT implant. 
 
Improvement of heart failure management 
Higher doses of both beta-blockers and renin angiotensin system blockers are associated with 
lower event rates,(115, 116) and the benefits of dose titration is especially important in 
patients at highest risk.(117) Although CRT is often considered only after implementation of 
optimal medical HF therapy, it needs to be emphasized that in clinical practice only a 
minority of patients are able to tolerate maximal doses of neurohormonal blockers before 
CRT implant.(75) On the other hand, the acute and chronic hemodynamic effects of CRT 
might significantly change tolerability and acceptance of medical therapy. For example, in the 
CARE-HF and COMPANION trial, CRT was associated with a 6-7 mmHg increase in 
systolic blood pressure.(3, 4) Furthermore, CRT protects patients against slowing of AV- 
conduction, bradycardia and sinoatrial nodal pauses allowing safe uptitration of beta-blockers. 
Two randomized controlled trials have tested higher versus lower doses of neuro-hormonal 
blockers in heart failure, indicating a lower event rate with higher doses.(115, 116) Attaining 
guideline directed doses of evidence based neurohormonal blockers is a cornerstone of the 
treatment of heart failure including patients with CRT devices which is insufficiently 
emphasized in current guidelines. Real world data indicate that 45% of patients on 
submaximal dose of ACE-I/ARB are able to tolerate uptitration following CRT-implant, and 
up to 57% of patients on submaximal dose of beta-blockers are able to tolerate higher doses 
after CRT-implant.(118) Although biased by the observational nature, uptitration was 
associated with a lower risk for heart failure hospitalization and mortality (118, 119). 
Furthermore, although between 73%-97% of patients were taking loop diuretics at the time of 
implant in the major CRT trials (1, 3, 4, 6, 47) loop diuretic down-titration is often feasible 
following CRT implant, with possible benefits on long term renal function.(120)  










Although initiation of sacubitril/valsartan improved outcome in the PARADIGM-HF trial, 
remarkably few were treated with CRT.(121) Sacubitril/valsartan use in CRT and ICD 
patients results in incremental reverse remodeling, and a significant reduction in the burden of 
VT/VF,  appropriate ICD therapies, and premature ventricular complexes (PVCs) which can 
have additional benefits on CRT delivery.(122-124)  
Although often underappreciated by patients and primary care physicians, physical exercise 
following CRT or ICD implant has proven to be safe in the ACTION-HF trial.(125) 
Furthermore, observational and randomized data suggested that cardiac rehabilitation 
following CRT implant is associated with a larger degree of functional improvement, LV 
reverse remodeling and reduction in heart failure hospitalization and mortality.(126-129)  
 
Optimal device programming  
Individual programming of devices following implant and at each follow-up should be the 
aim. At each clinic visit an electrocardiogram and device analysis may help with assessment 
of patient status. (Table 3). The key target of programming has been to deliver 100% of bi-
ventricular capture in order to achieve the optimal outcomes.(12, 23) Although no 
randomized controlled trials exist comparing a lower versus a higher degree of biventricular 
pacing, observational data link a low degree of biventricular pacing to poorer outcome. 
Although this might be to some extent a reflection of a different patient population, guidelines 
emphasize to try to attain a maximal percentage of biventricular pacing (Class IIa 
recommendation).(23) There are a range of other programmable options including pacing 
mode, pacing rate, upper tracking rate, rate-adaptive pacing, capture output, atrio-ventricular 
(AV) and ventriculo-ventricular (VV) intervals and tachy-programming which should be 
reviewed at each clinic visit.  










The pacing mode depends on the underlying atrial rhythm. In patients in sinus rhythm a DDD 
pacing mode is preferred but the base rate should allow sensing of intrinsic sinus rhythm as 
much as possible to avoid unnecessary atrial pacing. Landmark CRT trials often used a lower 
rate of 35-40/min with hysteresis off (130, 131). Atrial support pacing (base rate of 70/min in 
DDDR mode) did not show benefit in the PEGASUS-CRT trial,(132) possibly because right 
atrial pacing is associated with left atrial dyssynchrony and progressive left atrial remodeling, 
which also are independent predictors for the development of AF.(133-135) Therefore, lower 
rates are generally programmed low (40-50/min) in patients in sinus rhythm, although in 
patients in whom atrial fibrillation leads to mode switch, attention should be given to program 
a high enough base rate when this occurs (DDIR or VDIR mode). In patients in permanent AF 
an inhibited mode is preferred, which can be DDIR or VVIR depending on the presence of an 
atrial lead. The DDDR mode should be reserved for patients with paroxysmal AF.(12, 23) In 
patients with AF who receive adequate rate control, a slightly higher base rate of 60 bpm 
together with rate-adaptive pacing might improve the proportion of bi-ventricular capture.(12, 
23) However in those with sinus rhythm, rate-adaptive pacing should be programmed off until 
the presence of significant iatrogenic or intrinsic chronotropic incompetence affecting 
exercise intolerance is proven bearing in mind that simple age-related rate-adaptive pacing 
does not improve exercise capacity and may be disadvantageous in some.(117, 136, 137) 
Whether rate-adaptive pacing is activated or not, the upper tracking rate should be 
programmed sufficiently high (e.g. 80% of maximal age predicted heart rate), to ensure 
persistent biventricular pacing during periods of faster intrinsic sinus rhythm (e.g. exercise). 
Device diagnostics can be used to check this, although an exercise test is also useful.  
LV output should be programmed with sufficient margin to ensure biventricular capture. 
Modern devices are equipped with auto-capture features that might improve battery longevity 
in some,(138) although nocturnal threshold testing can be unpleasant if there is diaphragmatic 










capture at higher outputs. Quadripolar LV leads and their multiple vectors offer the 
opportunity of avoiding phrenic nerve stimulation, and output optimization to extend battery 
longevity,(139) whereas the use of multiple vectors simultaneously (multi-point pacing) has 
not shown clinical benefit whilst reducing battery life.(140)  
The most commonly assessed programming options include the AV and VV intervals. Poor 
attention to detail around especially AV delays is a contributor to reduced efficacy of 
CRT.(110) However, routine echocardiographic AV-interval optimization is not superior in 
comparison to empiric programming of a 100-120msec sensed AV-interval.(141) Most new 
devices from different vendors have automated algorithms that individualize AV/VV-
intervals, creating fusion between spontaneous conduction and LV stimulation to avoid right 
ventricular pacing, or optimizing AV/VV intervals using a hemodynamic sensor.(142, 143) 
None of these algorithms have proven to be superior to echocardiographic optimization, 
although a superiority study with LV fusion pacing is ongoing.(144) In the light of the neutral 
clinical results of a routine approach of optimizing AV and VV-intervals, one can consider 
this for specific patients (eg long interatrial delay). Nevertheless post-implant 
echocardiography with assessment of the mitral inflow pattern allows for a quick evaluation 
of the appropriateness of the AV-interval programming.  Indeed, if the A-wave is truncated or 
there is a lot of wasted mechanical time (fusion of E and A wave with A-wave ending before 
beginning of electrical systole), this should prompt the attention that the AV-interval is not 
programmed correctly. 
The programming of therapies for tachycardia should be individualized based on the 
indication for the ICD (primary vs secondary prevention) and has been reviewed in more 
detail recently.(145) Adequate brady- and tachyprogramming requires specialist device 
knowledge and expertise which aims at preventing morbidity, rather than to react to it (e.g. 
preventing ICD interventions; ensuring high biventricular-pacing; …). Therefore, these 










patients should be followed at specialized centers having multidisciplinary collaboration (i.e. 
heart failure and arrhythmology) and by physicians having undergone extensive device 
training and certification. 
 
Inclusion in remote monitoring  
In remote monitoring of CRT devices, a distinction should be made between device related 
remote monitoring and monitoring of heart failure status through measurement of 
physiological variables. Patients with CRT have heart failure, and are therefore at an 
increased risk of clinical events such as ventricular or supraventricular arrhythmias which can 
interrupt CRT or worsen heart failure status.(146) Additionally, technical problems related to 
battery and leads can have an impact on patients status and prognosis, and might warrant 
detection and appropriate action as early as possible. These variables can be monitored by the 
device and remotely transmitted to the treating team.(147) Early detection of clinical or 
technical issues improved clinical outcomes in the IN-TIME trial, (148) although several 
larger trials failed to show benefit of remote monitoring.(149-152) Large registries have 
shown benefits of remote monitoring in CRT patients especially when devices are capable of 
collecting multiple key physiological parameters such as heart rate, respiration frequency, 
heart sounds and physical activity, in addition to technical checks on the device.(23, 153) This 
approach requires an organizational change including funding of virtual visits and training of 
personnel who should react appropriately to transmitted information.(154) With the recent EU 
General Data Protection Regulation, hospitals and physicians must be aware of certain rules 
that need to be complied with and agreements with manufacturers that need to be in place to  
implement remote monitoring. Finally, patients preference should be taken into account, as 
observational data indicates that around 20-35% of patients prefer in-clinic visits instead of 
remote monitoring.(155)  
 










Managing Arrhythmias in CRT 
Arrhythmias are common in heart failure patients, and often have an impact on morbidity, 
mortality and functioning of the CRT device. Atrial tachyarrhythmias and frequent PVCs are 
responsible for 50% and 10% respectively of the cases of a low percentage of bi-ventricular 
pacing thereby further compromising LV systolic dysfunction and contributing to 
decompensation.(67, 156)  
Whether suppression of atrial tachyarrhythmia, mainly AF, in the presence of HFrEF is of 
benefit and which strategy might be appropriate is unknown.(157, 158) Despite concerns 
around long term safety and overall neutral clinical outcomes (154, 159), guidelines 
recommend amiodarone (IA) if a rhythm control strategy is chosen. AF-ablation has gained a 
lot of interest (IIA-recommendation),(24, 158) due to possible improvements in LVEF, 
functional capacity and quality of life in comparison to rate control in heart failure patients. 
(160-164) For example, long term follow-up of the highly-selected CASTLE-AF patients 
suggests that AF-ablation is associated with a lower risk of heart failure admission and all-
cause mortality.(161) Importantly, the benefit was demonstrated not by elimination of AF but 
rather by reducing overall AF burden.(161) In patients with HFrEF and AF who have a CRT 
device, AF-ablation could be considered for those with a high likelihood of attaining sinus 
rhythm and thus subsequently 100% of biventricular pacing. AV nodal ablation should be 
considered as a treatment strategy for patients who fail to achieve sufficient biventricular 
pacing despite AV-blocking medical therapy or efforts to maintain sinus rhythm (eg 
amiodarone or AF-ablation in selected patients). 
Frequent PVCs can also result in a low percentage of biventricular pacing and further worsen 
LV systolic function.(67) If despite heart failure therapy optimization, PVCs continue to 
cause low proportions of biventricular pacing, amiodarone or PVC-ablation can be 
considered.(158) A study in which patients with poor improvement after CRT and more than 










>10.000 PVCs per 24 hours were subjected to PVC-ablation showed improvements in 
symptoms and incremental reverse remodeling.(165)  
Ventricular arrhythmias are a key concern in HFrEF patients especially in those with 
reduced LVEF and ischemic heart disease. (83) The prevalence of ventricular arrhythmias is 
associated with the disease severity of HFrEF.(166-168) The event rate for mortality and heart 
failure admission are markedly higher following appropriate ICD-therapy, but not after 
inappropriate therapy,(169, 170) which indicates that a ventricular arrhythmic event in HFrEF 
is a marker of disease progression. Hence, heart failure therapy optimization is mandatory not 
only to treat, but also to prevent ventricular arrhythmias in HFrEF.(171) Additionally, triggers 
such as volume overload, ion disturbances, loss of biventricular pacing and others should be 
actively assessed and treated. Furthermore, guidelines recommend consideration of 
amiodarone and VT ablation in CRT-D patients after a first sustained episode.(171) Any 
arrhythmic event should also prompt a review of the device programming.(145) 
 
Disease progression and remission 
As indicated in Figure 2, CRT can stabilize the disease trajectory but some patients 
have persistent symptoms and will eventually deteriorate. Some of these patients might be 
indicated for advanced heart failure therapies. Therefore, the CRT specialist team should not 
only be experienced in the management of technical aspects of the CRT devices, and medical 
therapy for heart failure, but should also be competent to detect and understand the 
mechanisms underlying disease progression (see Figure 4). Imaging plays an essential role 
(172) in identifying persistence of secondary mitral regurgitation, and progressive atrial, LV 
and right ventricular remodeling all of which indicate progression of the HF syndrome, and 
warrant consideration of appropriate interventions,(173-175) including additional device 
therapies such as mitral edge-to-edge repair,(176, 177) or newer medical therapies.(121, 178) 










Cardiopulmonary exercise test with determination of peak VO2 and other variables might (29, 
179) provide information on prognosis and appropriate timing of more advanced interventions 
in selected patients.(180, 181) The CRT specialist team should be able to determine if 
palliative care is more suitable than onward referral for more invasive therapies.(182)  
CRT teams are also the best at determining whether and when the possibility for ICD-
interventions should be withdrawn. For example, at time of battery depletion and box-change, 
patient and physician perspective might warrant consideration of withdrawal of ICD therapy 
by replacement of a CRT-D device with a CRT-P device. (183-185) Unfortunately, this is 
increasingly difficult in the absence of a DF-4 to IS-1 connector necessitating an additional 
right ventricular pace-sense lead implantation. Additional liability issues might occur if 
patients, following downgrading from CRT-D to CRT-P, die suddenly  or subsequently show 
a deterioration in cardiac function, and therefore this should be comprehensively  discussed 
with the expert team and with the patient and/or his family and in the light of therapeutic aims 
and relevant co-morbidity, such as dementia or malignancy.  
A very small subgroup of CRT-patients demonstrate overwhelming benefit from CRT 
that every aspect of their heart failure disease seems to dissipate (normalization of 
echocardiogram and NTproBNP, and resolution of symptoms). These patients can be 
considered to be in „full remission‟. A small prospective randomized pilot trial suggested that 
closely supervised neurohumoral blocker withdrawal („CRT only strategy‟) is feasible and 
safe in patients with myocardial recovery after CRT.(186) These results differ from TRED-
HF in that those in TRED-HF did not have LBBB with improved LV function following 
CRT.(187) In contrast, data from MUSTIC and MADIT-CRT indicated that turning off 
biventricular pacing („medical strategy only‟) led to a reoccurrence of the heart failure 
syndrome.(7)  
 










Patient engagement and education 
CRT recipients are often older adults with multiple comorbidities. Adequate information on 
the purpose of CRT, the implant procedure including risk and post-implant care are essential 
for them and their family. A recent survey indicated that almost half of patients felt 
insufficiently informed about technical aspects or had worries about aspects of their 
implantable devices.(188) A considerable number of heart failure patients suffer from 
depressive symptoms which are associated with worse outcomes.(189) Psychosocial concerns 
and worries should be addressed in a multidisciplinary approach. Furthermore, end of life 
decisions such as ICD withdrawal are rarely discussed.(188) Information through healthcare 
providers (e.g. CRT-specialist, heart failure nurse) and paper and web-based education (e.g. 
www.heartfailurematters.org) might improve patients‟ understanding and engagement. Table 
4 summarizes important patient-centered aspects regarding the education of patients and 
families with regard to use of CRT. 
 
D. Future perspectives 
Alternative resynchronization strategies have been developed that might also effectively treat 
the electromechanical dyssynchrony in HFrEF patients. Such strategies include His-Bundle 
and LBBB-area pacing, endocardial LV lead pacing, wireless LV stimulation or even deep 
interventricular septal LV-pacing.(190-192) In patients with a classical CRT-indication, 
pacing strategies such as His-Bundle-pacing are often propagated as an alternative because of 
the equipoise induced by the 30% non-response rate to CRT.(193) However, it is clear from 
this manuscript that this concept of non-response to CRT is intrinsically flawed. Although 
acute hemodynamic and short-term reverse remodeling studies with these novel pacing 
strategies illustrate a similar hemodynamic, functional and remodeling improvement as CRT 
(191, 194-199), they will have to show at least equal benefit in terms of morbidity and 










mortality endpoints in  HFrEF and be as safe in order to be implemented in clinical practice as 
an alternative to CRT (198). Additionally, His-Bundle is also being tested in HFrEF for other 
indications such as PR-prolongation.(200) Whether CRT might be of benefit in patients with 
heart failure patients with preserved ejection fraction is also under investigation.(201)  
 
E.  Conclusion 
CRT is an underutilized lifesaving therapy, strongly recommended in guidelines for a 
common subgroup of HFrEF patients. This HFA, EHRA and EACVI endorsed document 
offers theoretical and practical strategies to achieve more comprehensive CRT referral and 
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Explanation: source is https://www.medtecheurope.org/wp-content/uploads/2016/03/CRM-Charts-
2018.pdf Abbreviations: CRT-P= cardiac resynchronization therapy pacemaker, CRT-D=cardiac 
































Explanation: visual depiction of the role of disease modification of CRT on the heart failure disease 
























Explanation: framework for individualizing CRT-P vs CRT-D to help patients who have not opted to 
avoid an ICD. Red indicates preference for CRT-P and green indicates preference for CRT-D. 
Balancing of choice is made by evaluating risk for SCD (yellow factors, with dark yellow indicating 
high SCD risk and light yellow indicating SCD risk) and the risk for non-SCD depicted in blue (dark 
blue indicates high risk for non-SCD and light blue indicates low risk for non-SCD). Abbreviations: 
CRT-D= cardiac resynchronization therapy defibrillator, CRT-P= cardiac resynchronization therapy 
defibrillator, ICMP= ischemic cardiomyopathy, SCD= sudden cardiac death, nsVT= non sustained 
ventricular tachycardia, EP= electrophysiology, NICMP=  non ischemic cardiomyopathy, PVC= 
premature ventricular complexes, NH= neurohormonal blockers, ESRD= endstage renal disease, ICD= 















Figure 4: Structured post-implant CRT-care 
 
Explanation: flowchart of essential elements of post-CRT care. Abbreviations: AF= atrial fibrillation, CRT= 
cardiac resynchronization therapy, ECG= electrocardiogram, GDMT= guideline directed medical therapy, GP= 
general practitioner, HF= heart failure, HTX= heart transplant, MCS= mechanical circulatory support, PCI= 
percutaneous coronary intervention, TAVI= transcatheter aortic valve implant, VT= ventricular tachycardia. * 
the evidence for remote monitoring for device related technical issues is stronger as for remote monitoring of 
heart failure parameters to detect worsening of heart failure, hence the different colors. ** Comorbidities often 
change during follow-up and also novel comorbidities need to be persistently addressed. The type of exercise test 
can be according to local expertise, but the aim is to see if there is persistent biventricular pacing during exercise 
or presence of chronotropic incompetence. The extent of application of this flowchart depends on the physical 
status (eg ability to perform an exercise test) , but also the eligibility towards more advanced therapies such as an 
LVAD or transplant.  










Table 1: myths and strategies for better implementation 
 
Common Myths of CRT Explanation 
Myths related to the pre-implant phase of CRT 
30% of patients do not respond to CRT CRT response has been classified by arbitrary definitions: 
its effect in any one individual should be seen as 
continuous disease modification and whilst they may not 
feel „better‟, they are highly likely to be „better than 
without the device‟ 
Patients with an ischemic etiology of 
heart failure benefit less from CRT 
On average, patients with an ischemic etiology of heart 
failure manifest less reverse remodeling but have an equal 
relative risk reduction after CRT for HF-admission and 
death as the non-ischaemic group 
If the QRS is narrow, patients will 
never have an indication for CRT 
In patients with HFrEF, remodeling of the left ventricle is 
accompanied by electrical remodeling such that QRS 
duration lengthens. Follow-up ECG are necessary. 
Consideration should be given to those with poor LV 
ejection fraction and a pacing indication that will lead to 
high proportion of RV pacing.  
CRT is an expensive therapy CRT is a cost-effective heart failure therapy.  
Consideration of CRT should only 
occur after repeated (failed) attempts 
to achieve guideline recommended 
doses of RAAS-I and beta blockers 
Only a minority of patients included in CRT trials were on 
optimal doses of RAAS-I and beta blockers, and the 
effects of these drugs on LVEF improvement are far less 
pronounced in LBBB than in narrow QRS. CRT can help 
achieve guideline recommended doses. 
Patients with multiple comorbidities 
derive no benefit of CRT 
Patients with comorbidities derive significant benefit from 
CRT, especially when the co-morbidities are addressed. 
The need for CRT-D should be dealt with openly in this 
population. 
All patients should receive CRT-D The benefit of the ICD is determined by the risk of sudden 
cardiac death over the risk of non-sudden cardiac death. 
Those at highest risk of HF death derive no benefit from 
an ICD.  
Physicians know when to refer patients 
for CRT. 
 
Most patients are only referred within cardiology. The 
non-cardiology medical and allied health community and 
patients need education to improve referral. 
Echocardiography should be used a 
technique to select patients that will 
not respond to CRT 
Echocardiography is poor at determining „need‟ or 
„response‟ to CRT. Patients should not be denied CRT 
based upon echocardiography.  










Access to CRT is not an issue as CRT 
implantation can be done by everyone 
who can implant a DDD-pacemakers 
CRT-implant does have a higher risk, and does require 
more training than conventional DDD-pacemakers. 
Efforts should be made to increase access. 
Myths related to the post-implant phase of CRT 
Optimization of CRT is only needed in 
non-responders 
 
Ideally, all CRT patients should receive regular review of 
their heart failure therapy which should include a review 
of medical treatment (including drug doses) and device 
programming. Not only is heart failure a progressive 
disease, such that adjustments can be of benefit, but recent 
and future developments in medical therapy should be 
applied to this group as rapidly as possible. 
Patients on CRT are on optimal 
medical therapy 
Only a minority are on optimal dosages of GDMT at the 
moment of implant, more than 60% can be further 
uptitrated after CRT 
Out of the box device programming 
suffices in most CRT patients 
All CRT patients should receive regular (at least annual) 
device checks and might need optimization of device 
settings (brady/tachy) by physicians specifically trained in 
cardiac device programming and troubleshooting. 
Remote monitoring is not useful Comprehensive remote monitoring including device/lead 
integrity, % of biventricular pacing and arrhythmias in 
CRT patients has been demonstrated to improve clinical 
outcome in at least 1 randomized trial with tightly 
controlled review and action systems in place. Regular 
device checks (at least once per year) remain important in 
patients undergoing remote monitoring.  
 
 
Abbreviations: AF= atrial fibrillation, BiV= Biventricular, CRT= cardiac resynchronization therapy, 
ECG= electrocardiogram, GDMT= guideline-line directed medical heart failure therapy,HF= heart 
failure, HFrEF= heart failure with reduced ejection fraction, LBBB= left bundle branch block, LVEF= 


























Table 2: Role and utility of interventions in CRT follow-up 
Intervention Potential relevance 
12-lead ECG  Ensure and determine BiV-paced complex (QRS width, degree of QRS 
reduction, capture, morphology and LV latency), ECG after implant is 
the template for future trouble-shooting 
 Consider performing at least once ECG with BiV off and LV and RV only 
pacing (large QRS difference between LV and RV only pacing might 
indicate need for VV-optimization) 
 Positive R-wave V1? If not, rule out LV lead displacement and loss of LV 
capture, and if other cause are negative if lead was placed in middle or 
anterior cardiac vein 
 Always repeat ECG following significant device changes 
Chest X-ray (PA 
and lateral) 
 Detect complication or comorbid condition such a pneumothorax, 
COPD, pleural effusion 




 Determine creatinine and potassium in patients with CKD as they 
received iv contrast, and neuro-hormonal blocker up-titration will 
follow 
 Consider determining Hb, ferritin and TSAT and treating iron 
deficiency accordingly 
Device analysis, 
consists of : 
 
1) Diagnostics  
2) Measurements 
3) Programming 
 Essential testing; battery status, lead impedance, sensing, pacing 
thresholds 
 Analyze device counters; BiV-pacing should be 100% (dedicated 
counters differ from company, quid percentage true BiV-pacing, e.g. 
LV-pace on ventricular sensed complexed), V-sensing should be 0%, 
assess PVC-burden (might be reason for low % BiV-pacing). High PVC 
burden can also indicate atrial undersensing or ventricular 
oversensing 
 Optimize brady and tachy-programming (see text) 
 Consider optimizing AV and VV interval 
 Assess presence of phrenic nerve stimulation at maximal LV-output 
 Assess atrial pacing vs atrial sensing %, aim to lower basic pacing rate 
to reduce unnecessary and deleterious atrial pacing. 
 Assess rate histograms; sufficient heart rate increase? Consider 
programming R-mode 
 Determine AT/AF burden; high AT/AF burden could be reason for 
low % BiV-pacing. Determine appropriateness of  mode switches 
(might be due to atrial oversensing, with DDI/VDI pacing as a result 
and potentially pacemaker syndrome) 
 Evaluate presence of VT/VF episode triggers (appropriate vs non-
appropriate) 
 Assess NsVT burden; high burden might be reason for low % of BiV-




 Detect potential new pericardial effusions 
 Consider evaluating the mitral inflow pattern, consider AV 
optimization in selected cases.  
 Consider assessing the effects of CRT pacing: acute vs chronic  










Exercise test  Ensure persistent BiV-pacing at high heart rate (solution: rate adaptive 
AV optimization) 
 Presence of chronotropic incompetence, best assessed once beta-
blocker up-titration is performed (need for R modus) 
Holter evaluation  Detection of QRS-fused beats if suspicion of intrinsic conduction fused 
beats (not detected by device counters) 
 Determine morphology of PVCs if frequent PVCs lead to low % of BiV-
pacing 
 Detect arrhythmias not detected by device, detect device malfunction 
 
Abbreviations: AT/AF= atrial tachycardia/ atrial fibrillation, AV= atrioventricular , 
BiV=biventricular pacing, COPD= chronic obstructive pulmonary disease,ECG= electrocardiogram, 
LV= left ventricular, MR= mitral regurgitation, NsVT= non-sustained ventricular tachycardia, PA= 
posterior-anterior, PVC= premature ventricular complexes, RV= right ventricular, VV= 
interventricular, VT/VF= ventricular tachycardia/ ventricular fibrillation. Explanation: diagnostic 
procedures should be individualized to the patients’ need and physical status and not be 
considered “routine” (e.g. repeat  treadmill tests in older adults, or those with frailty or co-





























Table 3: Template for CRT-device analysis 
 
Diagnostics 
1. Battery longevity 
2. %ASVP / %APVP / %Biv vs LV only / % Biv vs RVSense respons / % Effective 
3. Heart failure log: HR variability, activity, lung impedance, sleep… 
4. Arrhythmias (afib, ectopy, VT, Vsense response…) 








1. Lower / upper frequency  (+mode switch) 
2. R-response (accelerometer / CLS / minute ventilation) 
3. Biv vs RV vs LV only 
4. AV / VV times (manual: fixed vs dynamic / device-based) 
5. Output leads 
6. Sensitivity 




Abbreviations: APVP= atrial pace ventricular pace, ASVP= atrial sense ventricular pace, AV= 
atrioventricular,BiV= biventricular, CLS= closed loop stimulation, HR= heart rate, LV= left 






















 Table 4: Element of patient centered CRT-education 
 
Pre-implantation Early post-implantation Living with CRT 
 Discuss the position in 
the HF trajectory  
 Include patient and 
caregiver in decision 
making 
 Provide information 
and understanding of 
the device indication 
(ask-tell-ask) 
 Provide information on 
the procedure  
 Discuss expectations   
 Provide information of 
consequences  (long 
and short term) 
 Include family 
caregivers 
 Discussion of potential 
complications (lead 
displacement, shocks, 
infection) with the 
patients and care-giver. 
 Discuss questions 
related to discomfort, 
pain, placement   
 Discuss effect and 
expectations   
 Discuss the role of CRT 
in the HF treatment and 
consequence for 
treatment (lifestyle and 
medication changes)  
 Discuss how to adjust 
medications after 
implant 
 Inform on when to 
contact a health care 
provider 
 Include family 
caregivers 
 Provide tailored follow-
up 
 Discuss the role of CRT 
in the HF trajectory  
 Discuss consequences 
for survival, treatment, 
lifestyle, exercise  
 Be open for coping 
issues (feeling 
dependent on 
technology, anxiety for 
failure) 
 Inform the patients 
about relevant issues: 
insurance, travel 
 If relevant discuss 
deactivation of the ICD 
 Include family 
caregivers 
 End of life care. 
 
 
Abbreviations: CRT= cardiac resynchronization therapy, HF= heart failure, ICD= implantable 
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